| 効果 | 減少 |
| 試験方法 | 二重盲検法 |
| 試験期間 | 1-2 週間 |
| 被験者数 | 193 |
| 性別 | 男女 |
| 年齢 | 18-29, 30-44, 45-64, 65+ |
In persons with acute or chronic ear, nose or throat disorders given 10mg of serrapeptase thrice daily (30mg total), supplementation was more effective than placebo in reducing abnormalities of mucus production and swallowing and was also analgesic.
Effect Of Expectorants On Relaxation Behavior Of Sputum Viscoelasticity In Vivo
| 効果 | 減少 |
| 試験方法 | コホート法 |
| 試験期間 | 1-7 日 |
| 被験者数 | 40 |
| 性別 | 男女 |
| 年齢 | 18-29, 30-44, 45-64 |
In an open label study, serrapeptase (30mg daily) in persons with chronic respiratory disease (excluding asthma) was able to relax the viscoelasticity of sputum, confirming mucolytic properties in the lungs
The Effect Of An Orally Administered Proteolytic Enzyme On The Elasticity And Viscosity Of Nasal Mucus
| 効果 | 減少 |
| 試験方法 | コホート法 |
| 試験期間 | 2-4 週間 |
| 被験者数 | 24 |
| 性別 | 不明 |
Supplementation of serrapeptase at 30mg for 4 weeks in persons with chronic sinisitus was able to reduce the viscosity of nasal secretions without affecting the elasticity thereof.
Effect Of The Proteolytic Enzyme Serrapeptase In Patients With Chronic Airway Disease
| 効果 | 減少 |
| 試験方法 | コホート法 |
| 試験期間 | 2-4 週間 |
| 被験者数 | 29 |
| 性別 | 男女 |
In an open label study with 30mg serrapeptase (versus no treatment as control) in persons with chronic airway disease, serrapeptase was able to reduce sputum weight and neutrophil count as well as both its elasticity and viscosity over 4 weeks.